BioXcel Therapeutics (NASDAQ:BTAI) Lifted to “Buy” at ValuEngine

ValuEngine upgraded shares of BioXcel Therapeutics (NASDAQ:BTAI) from a hold rating to a buy rating in a report published on Thursday morning, ValuEngine reports.

Other equities research analysts also recently issued reports about the company. HC Wainwright set a $25.00 price target on BioXcel Therapeutics and gave the stock a buy rating in a report on Wednesday, August 21st. Zacks Investment Research raised BioXcel Therapeutics from a sell rating to a hold rating in a report on Wednesday, September 11th. Finally, BMO Capital Markets set a $21.00 price target on BioXcel Therapeutics and gave the stock a buy rating in a report on Wednesday, September 18th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. BioXcel Therapeutics currently has a consensus rating of Buy and a consensus price target of $19.75.

Shares of NASDAQ BTAI traded down $0.50 during mid-day trading on Thursday, hitting $5.30. 61,878 shares of the company were exchanged, compared to its average volume of 129,663. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.93 and a quick ratio of 3.93. The stock has a 50 day simple moving average of $8.42 and a 200-day simple moving average of $9.89. BioXcel Therapeutics has a 1-year low of $2.41 and a 1-year high of $12.00.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.02). Sell-side analysts forecast that BioXcel Therapeutics will post -2.22 EPS for the current year.

In related news, CEO Vimal Mehta purchased 2,983 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was purchased at an average cost of $8.64 per share, with a total value of $25,773.12. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Frank Yocca acquired 6,547 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was acquired at an average price of $8.67 per share, with a total value of $56,762.49. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 18,976 shares of company stock valued at $165,104. Corporate insiders own 64.80% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Artemis Investment Management LLP increased its holdings in BioXcel Therapeutics by 21.6% in the 3rd quarter. Artemis Investment Management LLP now owns 1,190,184 shares of the company’s stock worth $8,365,000 after acquiring an additional 211,169 shares in the last quarter. Vanguard Group Inc. increased its holdings in BioXcel Therapeutics by 45.4% in the 2nd quarter. Vanguard Group Inc. now owns 259,301 shares of the company’s stock worth $2,842,000 after acquiring an additional 80,959 shares in the last quarter. BlackRock Inc. increased its holdings in BioXcel Therapeutics by 1,988.0% in the 2nd quarter. BlackRock Inc. now owns 299,145 shares of the company’s stock worth $3,278,000 after acquiring an additional 284,818 shares in the last quarter. Northern Trust Corp increased its holdings in BioXcel Therapeutics by 247.7% in the 2nd quarter. Northern Trust Corp now owns 43,822 shares of the company’s stock worth $481,000 after acquiring an additional 31,218 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in BioXcel Therapeutics by 59.8% in the 2nd quarter. Renaissance Technologies LLC now owns 71,600 shares of the company’s stock worth $785,000 after acquiring an additional 26,800 shares in the last quarter. Hedge funds and other institutional investors own 19.05% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

See Also: Why are analyst ratings important in trading stocks?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.